These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31322176)

  • 41. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Terzi H; Altun A; Şencan M
    Indian J Med Res; 2019 Dec; 150(6):630-634. PubMed ID: 32048627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells.
    Wang JH; Zhou WW; Cheng ST; Liu BX; Liu FR; Song JQ
    Mol Med Rep; 2015 Aug; 12(2):1810-6. PubMed ID: 25825239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
    Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
    J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
    Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
    Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
    Chen RA; Tu Y; Cao Y; Liu L; Liang Y
    J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
    Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
    Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
    Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib.
    Francisco V; Ruiz-Fernández C; González-Rodríguez M; Cordero-Barreal A; Pino J; Viñuela JE; Lago F; Conde J; Gómez R; Carvalho GR; Costa Pereira TM; Campos-Toimil M; Gualillo O
    J Ethnopharmacol; 2021 May; 272():113932. PubMed ID: 33609728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells].
    Dong HJ; Chen XQ; Gao GX; Gu HT; Pan YZ; Gao Y; Zhu HF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):107-10. PubMed ID: 19236758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.